Compared with classical platinum-based chemotherapy or docetaxel, immune checkpoint inhibitors (ICIs), such as programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1), for treatment of NSCLC demonstrated superior survival [2]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.